Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Assessment of 19 Genes and Validation of CRM Gene Panel for Quantitative Transcriptional Analysis of Molecular Rejection and Inflammation in Archival Kidney Transplant Biopsies.

Sigdel T, Nguyen M, Liberto J, Dobi D, Junger H, Vincenti F, Laszik Z, Sarwal MM.

Front Med (Lausanne). 2019 Oct 1;6:213. doi: 10.3389/fmed.2019.00213. eCollection 2019.

2.

Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.

Harel E, Shoji J, Abraham V, Miller L, Laszik ZG, King A, Dobi D, Szabo G, Hann B, Sarwal MM, Craik CS, Vincenti F.

Transplantation. 2020 Jan;104(1):54-60. doi: 10.1097/TP.0000000000002930.

PMID:
31449183
3.

A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.

Vincenti F, Klintmalm G, Yang H, Ram Peddi V, Blahunka P, Conkle A, Santos V, Holman J.

Am J Transplant. 2020 Jan;20(1):172-180. doi: 10.1111/ajt.15560. Epub 2019 Sep 9.

4.

Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.

Pascual J, Berger SP, Chadban SJ, Citterio F, Kamar N, Hesselink DA, Legendre C, Eisenberger U, Oppenheimer F, Russ GR, Sommerer C, Rigotti P, Srinivas TR, Watarai Y, Henry ML, Vincenti F, Tedesco-Silva H.

Transplant Rev (Orlando). 2019 Oct;33(4):191-199. doi: 10.1016/j.trre.2019.07.001. Epub 2019 Jul 23. Review.

PMID:
31377099
5.

Combination of pressurized liquid extraction with dispersive liquid liquid micro extraction for the determination of sixty drugs of abuse in hair.

Vincenti F, Montesano C, Cellucci L, Gregori A, Fanti F, Compagnone D, Curini R, Sergi M.

J Chromatogr A. 2019 Nov 8;1605:360348. doi: 10.1016/j.chroma.2019.07.002. Epub 2019 Jul 3.

PMID:
31315812
6.

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.

Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D.

Am J Transplant. 2019 Nov;19(11):3035-3045. doi: 10.1111/ajt.15514. Epub 2019 Jul 23.

7.

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.

Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J; TRANSFORM investigators.

Am J Transplant. 2019 Nov;19(11):3018-3034. doi: 10.1111/ajt.15480. Epub 2019 Jul 1.

PMID:
31152476
8.

Characterizing pre-transplant and post-transplant kidney rejection risk by B cell immune repertoire sequencing.

Pineda S, Sigdel TK, Liberto JM, Vincenti F, Sirota M, Sarwal MM.

Nat Commun. 2019 Apr 23;10(1):1906. doi: 10.1038/s41467-019-09930-3.

9.

Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.

Harel E, Shoji J, Abraham V, Miller L, Laszik Z, Thurison T, King A, Olshen A, Leung J, Szabo G, Hann B, Høyer-Hansen G, Craik CS, Vincenti F.

Clin Transplant. 2019 Mar;33(3):e13487. doi: 10.1111/ctr.13487. Epub 2019 Feb 21.

PMID:
30689221
10.

A syn-ent-labdadiene derivative with a rare spiro-β-lactone function from the male cones of Wollemia nobilis.

Venditti A, Frezza C, Vincenti F, Brodella A, Sciubba F, Montesano C, Franceschin M, Sergi M, Foddai S, Di Cocco ME, Curini R, Delfini M, Bianco A, Serafini M.

Phytochemistry. 2019 Feb;158:91-95. doi: 10.1016/j.phytochem.2018.11.012. Epub 2018 Nov 24.

PMID:
30481664
11.

Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial.

Busque S, Vincenti FG, Tedesco Silva H, O'Connell PJ, Yoshida A, Friedewald JJ, Steinberg SM, Budde K, Broeders EN, Kim YS, Hahn CM, Li H, Chan G.

Transplant Direct. 2018 Aug 8;4(9):e380. doi: 10.1097/TXD.0000000000000819. eCollection 2018 Sep.

12.

Nuclear Factor of Activated T Cell-regulated Cytokine Gene Expression for Adjustment of Tacrolimus in Kidney Transplant Recipients: A Randomized Controlled Pilot Trial.

Webber AB, Tatapudi V, Maw TT, Peralta C, Leung JCY, Vincenti F.

Transplant Direct. 2018 Jun 27;4(7):e369. doi: 10.1097/TXD.0000000000000810. eCollection 2018 Jul.

13.

Targeted Transcriptional Profiling of Kidney Transplant Biopsies.

Sigdel TK, Nguyen M, Dobi D, Hsieh SC, Liberto JM, Vincenti F, Sarwal MM, Laszik Z.

Kidney Int Rep. 2018 Feb 3;3(3):722-731. doi: 10.1016/j.ekir.2018.01.014. eCollection 2018 May.

14.

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.

Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators.

J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11.

15.

A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.

Vincenti F, Budde K, Merville P, Shihab F, Ram Peddi V, Shah M, Wyburn K, Cassuto-Viguier E, Weidemann A, Lee M, Flegel T, Erdman J, Wang X, Lademacher C.

Am J Transplant. 2018 Dec;18(12):2945-2954. doi: 10.1111/ajt.14925. Epub 2018 Jun 20.

16.

Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.

Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Yang L, Medina Pestana J, Larsen CP.

Clin Transplant. 2018 Apr;32(4):e13225. doi: 10.1111/ctr.13225. Epub 2018 Mar 14.

PMID:
29461660
17.

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.

Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J; Focal Segmental Glomerulosclerosis Study Group.

Kidney Int Rep. 2017 Apr 7;2(5):800-810. doi: 10.1016/j.ekir.2017.03.011. eCollection 2017 Sep.

18.

Identification of MT-45 Metabolites: In Silico Prediction, In Vitro Incubation with Rat Hepatocytes and In Vivo Confirmation.

Montesano C, Vannutelli G, Fanti F, Vincenti F, Gregori A, Rita Togna A, Canazza I, Marti M, Sergi M.

J Anal Toxicol. 2017 Oct 1;41(8):688-697. doi: 10.1093/jat/bkx058.

PMID:
28985323
19.

Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients.

Wojciechowski D, Chandran S, Webber A, Hirose R, Vincenti F.

Transplant Proc. 2017 Oct;49(8):1773-1778. doi: 10.1016/j.transproceed.2017.06.030.

PMID:
28923623
20.

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.

Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyó J, Meier-Kriesche HU, Polinsky M, Yang L, Larsen CP.

Am J Transplant. 2017 Dec;17(12):3219-3227. doi: 10.1111/ajt.14452. Epub 2017 Sep 5.

21.

Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants.

Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F.

Am J Transplant. 2017 Nov;17(11):2945-2954. doi: 10.1111/ajt.14415. Epub 2017 Aug 14.

22.

Transplant trials with Tregs: perils and promises.

Tang Q, Vincenti F.

J Clin Invest. 2017 Jun 30;127(7):2505-2512. doi: 10.1172/JCI90598. Epub 2017 Jun 30. Review.

23.

Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience.

Wojciechowski D, Chandran S, Yang JYC, Sarwal MM, Vincenti F.

Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13042. Epub 2017 Jul 21.

PMID:
28662293
24.

Belatacept: the challenges with transformational drugs.

Vincenti F.

Transl Androl Urol. 2017 Apr;6(2):341-342. doi: 10.21037/tau.2017.03.07. No abstract available.

25.

B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function.

Asare A, Kanaparthi S, Lim N, Phippard D, Vincenti F, Friedewald J, Pavlakis M, Poggio E, Heeger P, Mannon R, Burrell BE, Morrison Y, Bridges N, Sanz I, Chandraker A, Newell KA, Turka LA.

Am J Transplant. 2017 Oct;17(10):2627-2639. doi: 10.1111/ajt.14283. Epub 2017 May 2.

26.

Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.

Wojciechowski D, Chandran S, Vincenti F.

Clin Transplant. 2017 May;31(5). doi: 10.1111/ctr.12930. Epub 2017 Mar 28.

PMID:
28190259
27.

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.

Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N.

Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23.

28.

Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials.

Klintmalm GB, Vincenti F, Kirk A.

Am J Transplant. 2016 Nov;16(11):3077-3078. doi: 10.1111/ajt.13889. Epub 2016 Jul 1. No abstract available.

29.

Current status of costimulatory blockade in renal transplantation.

Wojciechowski D, Vincenti F.

Curr Opin Nephrol Hypertens. 2016 Nov;25(6):583-590. Review.

PMID:
27517137
30.

Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2.

Wojciechowski D, Vincenti F.

Adv Chronic Kidney Dis. 2016 Sep;23(5):306-311. doi: 10.1053/j.ackd.2016.09.004. Review.

PMID:
27742385
31.

Belatacept and Long-Term Outcomes in Kidney Transplantation.

Vincenti F.

N Engl J Med. 2016 Jun 30;374(26):2600-1. doi: 10.1056/NEJMc1602859. No abstract available.

PMID:
27355541
32.

An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.

Webber AB, Vincenti F.

Transplantation. 2016 Apr;100(4):836-43. doi: 10.1097/TP.0000000000000872. Review.

PMID:
27003097
33.

Belatacept and Long-Term Outcomes in Kidney Transplantation.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP.

N Engl J Med. 2016 Jan 28;374(4):333-43. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med. 2016 Feb 18;374(7):698.

34.

A Computational Gene Expression Score for Predicting Immune Injury in Renal Allografts.

Sigdel TK, Bestard O, Tran TQ, Hsieh SC, Roedder S, Damm I, Vincenti F, Sarwal MM.

PLoS One. 2015 Sep 14;10(9):e0138133. doi: 10.1371/journal.pone.0138133. eCollection 2015.

35.

A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.

Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, Yue S, Vincenti F.

Transplantation. 2016 Jan;100(1):184-93. doi: 10.1097/TP.0000000000000823.

36.

Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.

Vincenti F, Silva HT, Busque S, O'Connell PJ, Russ G, Budde K, Yoshida A, Tortorici MA, Lamba M, Lawendy N, Wang W, Chan G.

Am J Transplant. 2015 Jun;15(6):1644-53. doi: 10.1111/ajt.13181. Epub 2015 Feb 3.

37.

The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study.

Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, Metes D, Zeevi A, Gritsch A, Cheeseman J, Macedo C, Peddy R, Medeiros M, Vincenti F, Asher N, Salvatierra O, Shapiro R, Kirk A, Reed EF, Sarwal MM.

PLoS Med. 2014 Nov 11;11(11):e1001759. doi: 10.1371/journal.pmed.1001759. eCollection 2014 Nov. Erratum in: PLoS Med. 2015 Feb;12(2):e1001790. Zeevi, Andrea [corrected to Zeevi, Adriana]; Reed, Elaine [corrected to Reed, Elaine F].

38.

Role of podocyte B7-1 in diabetic nephropathy.

Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D'Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH.

J Am Soc Nephrol. 2014 Jul;25(7):1415-29. doi: 10.1681/ASN.2013050518. Epub 2014 Mar 27.

39.

Clinical aspects: focusing on key unique organ-specific issues of renal transplantation.

Chandran S, Vincenti F.

Cold Spring Harb Perspect Med. 2014 Feb 1;4(2). pii: a015644. doi: 10.1101/cshperspect.a015644. Review.

40.

Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.

Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondragón-Ramirez GA, Kothari J, Pupim L, Larsen CP.

Am J Transplant. 2013 Nov;13(11):2875-83. doi: 10.1111/ajt.12460. Epub 2013 Sep 18.

41.

Tofacitinib in kidney transplantation.

Wojciechowski D, Vincenti F.

Expert Opin Investig Drugs. 2013 Sep;22(9):1193-9. doi: 10.1517/13543784.2013.811231. Epub 2013 Jul 11. Review.

PMID:
23841583
42.

Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma.

van Gelder T, Baan C, Vincenti F, Mannon RB.

Transpl Int. 2013 Sep;26(9):938-48. doi: 10.1111/tri.12140. Epub 2013 Jul 4.

43.

Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans.

Vagefi PA, Qian JJ, Carlson DM, Aparici CM, Hirose R, Vincenti F, Wojciechowski D.

Transpl Int. 2013 May;26(5):471-6. doi: 10.1111/tri.12066. Epub 2013 Feb 6.

44.

Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update.

Wojciechowski D, Vincenti F.

Biologics. 2012;6:385-93. doi: 10.2147/BTT.S23561. Epub 2012 Nov 2.

45.

Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study.

Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, Scheuermann EH, Klinger M, Russ G, Pescovitz MD, Prestele H.

Am J Transplant. 2013 Jan;13(1):136-45. doi: 10.1111/j.1600-6143.2012.04320.x. Epub 2012 Nov 8.

46.

Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year.

Wojciechowski D, Chanda R, Chandran S, Lee B, Webber A, Macaraig M, Tomlanovich S, Vincenti F.

Transplantation. 2012 Dec 15;94(11):1117-23. doi: 10.1097/TP.0b013e31826ec74e.

PMID:
23060281
47.

Belatacept in kidney transplantation.

Wojciechowski D, Vincenti F.

Curr Opin Organ Transplant. 2012 Dec;17(6):640-7. doi: 10.1097/MOT.0b013e32835a4c0d. Review.

PMID:
23044530
48.

Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients.

Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F.

Transpl Int. 2012 Dec;25(12):1257-67. doi: 10.1111/j.1432-2277.2012.01565.x. Epub 2012 Sep 21.

49.

Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study.

Grinyo J, Alberu J, Contieri FL, Manfro RC, Mondragon G, Nainan G, Rial Mdel C, Steinberg S, Vincenti F, Dong Y, Thomas D, Kamar N.

Transpl Int. 2012 Oct;25(10):1059-64. doi: 10.1111/j.1432-2277.2012.01535.x. Epub 2012 Jul 21.

50.

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G.

Am J Transplant. 2012 Sep;12(9):2446-56. doi: 10.1111/j.1600-6143.2012.04127.x. Epub 2012 Jun 8.

Supplemental Content

Loading ...
Support Center